4 posts Page 1 of 1
Good morning.

One product is currently in clinical test, 2B phase, driven by Geneuro, a biotech Company in Switzerland.
This test is for relapsing MS. Preliminary results should be given during the fourth quarter in 2017. Very soon, as it is also for progressive SEP, clinical tests should be started in US in the following months.

Here is one video from the general direcctor, in French but english subtitles are available :

Is it always like this?
Some news from Miguel Payro, financial Manager of Geneuro Company.
Youtube video with english subtitles:

Is it always like this?
For those of you, who prefer a written press release in English, I found this press release:
http://www.geneuro.ch/data/news/GeNeuro ... 17-ENG.pdf
But note, that after 6 months of treatment with the antibody GNbAC1, which is said to neutralize the p HERV-W env ancestral retrovirus blamed for neuroinflammation, they could not observe any significant differences between treatment group and placebo group regarding lesions visible in MRI.
They expect to be able to present data from the extension of the trial (12 months of treatment) at the end of the first quarter of 2018.
Best wishes
Hi Zoe,

you're right regarding the first announcement for the results at 6 months.

BUT, during ECTRIMS meeting in Paris, Geneuro indicated for the post hoc analysis of the results, they had remyelination evidence, and that in fact it appears that the process action of their product was just longer.

Please see again the Miguel Payro video.

I made english subtitles, you can access to it clicking on the windows.

Have a good day
Is it always like this?
4 posts Page 1 of 1

Who is online

Users browsing this forum: No registered users and 2 guests